FDA Approves Pirtobrutinib for R/R Mantle Cell Lymphoma FDA Approves Pirtobrutinib for R/R Mantle Cell Lymphoma

This drug is the first BTK inhibitor approved to treat mantle cell lymphoma in this setting. Approval was based on overall response rates and duration of response in the phase 1/2 BRUIN trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news